A multicenter prospective registry (STA2R) is conducted to assess systemic treatments for alopecia areata, focusing on effectiveness, safety, and long-term outcomes.
Eligibility
Sex
ALL
Min age
16 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Diagnosed with alopecia areata;
* Starting/using a systemic treatment for alopecia areata;
* Informed consent for registry participation obtained from patient and/or caretaker.
Exclusion Criteria:
* Not sufficiently capable of understanding the Dutch language;
* Not willing to participate.
Primary outcome measure(s)
Effectiveness of systemic treatments — A minimum of 10 years from last patient enrolled (every 3-6 months) The primary study parameters and endpoints include assessing the short- and long-term effectiveness of various systemic treatments for alopecia areata. Effectiveness ranging from strong improvement to strong deterioration (5 categories).
Safety of systemic treatments — A minimum of 10 years from last patient enrolled (every 3-6 months) The primary study parameters and endpoints include assessing the short- and long-term safety of various systemic treatments for alopecia areata. Measured by the number of participants with treatment-related adverse events.
Trial sites (1)
Facility
City
Region
Status
Erasmus University Medical Center
Rotterdam
Netherlands
Recruiting
More Erasmus Medical Center trials in the Netherlands
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
